ClinicalTrials.gg
Status unknownNCT03747731KIDNEY-LUNGUpdated Feb 1, 2019

A Non-invasive Evaluation of Kidney-Lung Interactions

An observational study in Perfusion; Complications and Mechanical Ventilation Complication, sponsored by St. Bortolo Hospital. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by St. Bortolo Hospital · Observational

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
109
Ages
18 Years and older
Sex
All
01

Study summary

The present study aims to evaluate, with non-invasive methods, the relationships existing between PEEP and renal perfusion in patients undergoing surgery and requiring ventilatory support and monitoring in intensive care. Renal perfusion will be assessed at baseline (PEEP 0), subsequently ,at the application of progressive increases of PEEP. At the end of the measurements, the implications of the use of PEEP on the renal vascular system will be analyzed.

Read the detailed description

The present physiological, monocentric, observational clinical study evaluates the effect of progressive PEEP increases on renal perfusion in mechanically ventilated patients who underwent surgery with the need of ventilatory support and monitoring in intensive care.

Precisely, will be evaluated:

  • The morphometric parameters (coronal diameter and cortico-medullary thickness) and the renal resistive indices (IR). The inter-lobar arteries will be sampled and the IRs will be measured as the upper and lower level and the mesorenes. Measurements will be performed both in the kidney and in baseline conditions and incremental values of PEEP (0 - 6 - 12).
  • Gas exchanges, FC, systolic BP, diastolic and mean, Pmax, P1 and P2 of the airways, total and ohmic resistances and static respiratory compliance indexed for weight body (RRSmaxI, RRSminI, CrsI will be recorded).

The intra-class correlation coefficient will be measured to estimate the intra-observer reproducibility of the conducted measurement.

02

Conditions studied

  • Perfusion; Complications
  • Mechanical Ventilation Complication

Keywords

  • Renal blood perfusion
  • Mechanical ventilation
03

In context

Lead sponsor

St. Bortolo Hospital is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgery and with the need for ventilatory support for the intensive care unit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 Years and older
  • Receiving mechanical ventilation, invasive blood pressure monitoring and an urinary catheter to monitor diuresis
  • Need for postoperative monitoring in intensive care
  • Written ;

Exclusion criteria

Exclusion Criteria:

  • Acute kidney injury defined according to KDIGO guidelines;
  • Pre-existing chronic renal disease;
  • Heart failure;
  • ARDS;
  • Sepsis and Septic Shock;
  • Hemodynamic instability with the need for vasoactive support;
  • Chronic or occasional therapy with drugs that could modify the renal blood flow and that can not be suspended two days before the study (Vasoactive agents, Ace-inhibitors, Beta-blockers, NSAIDs, Sartans and Diuretics therapy);
  • Presumed or established state of pregnancy;
  • Refusal of ;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
109 participants (estimated)
Patient registry
No

Groups and cohorts

  • Resistive Index and Peep Titration

    Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney. Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level. The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period.

06

What researchers measure

Primary outcomes

  1. Association between IR and PEEP

    Resistive index will be measured in both kidney and recorded using multifrequency convex probe.The association between positive end expiratory pressure and resistive index will be analyzed as the primary outcome.

    Time frame: Change from baseline to 60 minutes

Secondary outcomes

  1. Association between PEEP and Hemodynamics Paramenters

    Resistive index will be measured in both kidney and recorded using multifrequency convex. FC, systolic, diastolic and mean PA will be measured at each PEEP level

    Time frame: Change from baseline to 60 minutes

Other outcomes

  1. Association between IR and Respiratory exchanges

    Resistive index will be measured in both kidney and recorded using multifrequency convex. PaO2 and PaCO2 will be analyzed at each PEEP level.

    Time frame: Change from baseline to 60 minutes

07

Study locations

1 of 1 sites recruiting
  • San Bortolo Hospital
    Vicenza, 36100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for May 2019, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2018
First posted
Nov 20, 2018
StartActual
Nov 19, 2018
Primary completionEst.
May 19, 2019
CompletionEst.
Nov 19, 2019
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747731
Lead sponsor
St. Bortolo Hospital
Responsible party
Silvia De Rosa (Medical Doctor, St. Bortolo Hospital) — Principal investigator
First posted
Nov 20, 2018
Start date
Nov 19, 2018
Primary completion
May 19, 2019 (estimated)
Completion
Nov 19, 2019 (estimated)
Last update
Feb 1, 2019

Study contacts

Silvia De Rosa, MD
Contact
derosa.silvia@ymail.com
+393933098583
Silvia De Rosa, MD
principal investigator · Ospedale San Bortolo di Vicenza

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion